ANG-3070 in Healthy Adult Participants

NCT04196179 ↗

Phase 1 Completed 97 enrolled Angion Biomedica Corp

RandomizedSequentialDouble-blindTreatment

Summary

This is a Phase 1 study, to assess the safety, tolerability, pharmacokinetics, and food effect of single and multiple ascending doses of ANG-3070 in healthy adult participants. This study is comprised of 12 cohorts. 5 single ascending dose (SAD) cohorts 6multiple ascending dose (MAD) cohorts, and 1 single dose food effect (FE) cross-over cohort Each cohort will have a total of 8 subjects: SAD and MAD (2 subjects receiving placebo and 6 subjects receiving active ANG-3070)

Timeline

Start: 2019-12-17
Primary completion: 2020-11-27
Completion: 2021-03-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ANG-3070	Unknown	50 mg	Oral
Subject	ANG-3070	Unknown	100 mg	Oral
Subject	ANG-3070	Unknown	200 mg	Oral
Subject	ANG-3070	Unknown	250 mg	Oral
Subject	ANG-3070	Unknown	400 mg	Oral
Subject	ANG-3070	Unknown	500 mg	Oral
Subject	ANG-3070	Unknown	600 mg	Oral

Indications

No indication recorded.